Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alexion | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alexion

Revenues up 48% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion
 
2Q Revenues:  $274.7 million (+48%)
 
2Q Earnings: $36.3 million (+5%)
 
YTD Revenues: $519.5 million (+48%)
 
YTD Earnings: $81.7 million (+33%)
 
Comments: Revenues were driven by Soliris, which added the indication of atypical hemolytic uremic syndrome late last year. R&D expenses rose 70% to $60 million as the company advanced several drugs in its pipeline.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters